Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 19;8(12):e84088.
doi: 10.1371/journal.pone.0084088. eCollection 2013.

Economic impact of a triptan Rx-to-OTC switch in six EU countries

Aurelie Millier  1 , Joshua Cohen  2 , Mondher Toumi  3
Affiliations

Economic impact of a triptan Rx-to-OTC switch in six EU countries

Aurelie Millier et al. PLoS One. .

Abstract

Introduction: Triptans have been safely and effectively used in the management of migraine for more than fifteen years, and it seems reasonable to wonder what would be the economic impact of moving a specific triptan to OTC availability. The objective of this study was then to examine the economic impact of payer policies of a triptan Rx-to-OTC switch in six EU countries (France, UK, Spain, Italy, Germany and Poland).

Methods: A decision model was used to model the budgetary impact of a triptan Rx-to-OTC switch from the third-party payer (TPP) and the societal perspectives, using a one-year timeframe.

Results: From the TPP perspective, it is estimated that the current overall direct spending on the management of migraine attacks across the 6 EU Member States is €582 million annually, and that the savings would reach €75 million (13% of the overall direct economic burden of migraine). From the societal perspective, €86 million annually would be added.

Conclusions: Given evidence of effectiveness and safety, and given the potential savings, a triptan Rx-to-OTC switch is a reasonable public policy decision.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Aurélie Millier is an employee from Creativ-Ceutical, which received funding from Sanofi. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Similar articles

See all similar articles

Cited by

References

    1. Villalón CM, Centurión D, Valdivia LF, de VP, Saxena PR (2003) Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol 1: 71-84. doi:10.2174/1570161033386826. PubMed: 15320857. - DOI - PubMed
    1. Abel H (2009) Migraine headaches: diagnosis and management. Optometry 80: 138-148. doi:10.1016/j.optm.2008.06.008. PubMed: 19264290. - DOI - PubMed
    1. Stovner LJ, Tronvik E, Hagen K (2009) New drugs for migraine. J Headache Pain 10: 395-406. doi:10.1007/s10194-009-0156-9. PubMed: 19795182. - DOI - PMC - PubMed
    1. Yu J, Goodman MJ, Oderda GM (2009) Outcomes and economics in pain and palliative care. Journal of Pain and Palliative Care Pharmacotherapy 23: 693-408. - PubMed
    1. World Health Organization. 2006.

Publication types

MeSH terms